Where this publication takes a position
Most of this site reports. A smaller part of it argues. This page is the line between the two, drawn where a reader can see it.
The short answer
8 pieces of analysis and 4 running ledgers. A ledger reports what a statute, a registry or a price list says and gets out of the way. Analysis reads the same material and states a conclusion the sources do not state themselves — labeled as ours, with the evidence beside it. Publications in this field mix the two freely, which is how a reader ends up treating somebody’s reading of a trial as the trial’s own result.
Analysis
The pieces where we take a view
Each of these reads a body of evidence and reaches a conclusion of its own. The conclusion is marked as ours, and the sources sit on the same page, so you can follow the reasoning and take a different view of it.
- AnalysisReviewed 2026-09-01
Oregon has 378 licensed facilitators and 21 places to work
Oregon licensed roughly eighteen psilocybin facilitators for every venue where a session may lawfully happen, and the state publishes no data that would say how many of them are in Oregon.
Read it - AnalysisReviewed 2026-08-31
Commonly misreported
The trial that supposedly beat escitalopram missed its primary outcome at p=0.17, and its famous figures are unadjusted secondary outcomes the authors themselves say carry no clinical conclusion.
Read it - AnalysisReviewed 2026-08-31
Two federal agencies, one substance, two descriptions
The DEA lists possible death among overdose effects and NIDA calls psilocybin low-toxicity. Both are current federal publications, only one of the five compared topics is a real conflict, and the rest is a difference of remit that nobody citing either page mentions.
Read it - AnalysisReviewed 2026-08-31
Why a faster review keeps getting read as an approval
Three sponsors hold priority vouchers that compress FDA review to one or two months. That is a shorter queue, not a decision, and every state trigger law waits on both FDA approval and DEA rescheduling.
Read it - AnalysisReviewed 2026-08-31
The advice to taper first is weaker than it sounds
Two weeks of escitalopram left positive mood and mystical-type experience unchanged, and a 2024 analysis found psilocybin's advantage disappeared specifically among recent discontinuers — which points the other way from the advice most people are given.
Read it - AnalysisReviewed 2026-08-31
Decriminalized and legal are not the same word
Decriminalization removes a criminal penalty for possession. It creates no lawful supply, no standard for who may supervise, and no recourse when something goes wrong — and it is reported as legalization almost every time.
Read it - AnalysisReviewed 2026-08-31
Which psychedelic conferences are scientific meetings
Every listing site in this field prints a peer-reviewed congress and a wellness weekend in the same typeface at the same price. We classify each event by what it actually is, and the classification is ours rather than the organizer's.
Read it - AnalysisReviewed 2026-08-31
Twelve countries we can show you the source for
The comparable resource covers fifty-plus countries and says openly that its authors are neither lawyers nor residents. We publish twelve, each marked by whether we read the government page ourselves, and the list grows by verification rather than by addition.
Read it
Ledger
The records we keep current
A living record, assembled from primary sources — a statute, a registry, a published price — and carrying the date it was last checked against them, so you can see how fresh it is before you rely on it.
- LedgerReviewed 2026-08-31
Psilocybin law in all 51 US jurisdictions
Every state and DC, with the statute, the local ordinances and the penalties — including the states other trackers report incorrectly.
Read it - LedgerReviewed 2026-08-31
Trials open to new participants
Pulled from ClinicalTrials.gov and filtered to studies actually recruiting, with the medication-washout requirement surfaced rather than buried — it is the criterion that disqualifies most people who apply.
Read it - LedgerReviewed 2026-08-31
What supervised psilocybin actually costs
Published prices from licensed Oregon and Colorado centers, with the fees that sit outside the headline number. No insurer covers any of it.
Read it - LedgerReviewed 2026-08-31
The psilocybin drug development pipeline
Who is running what, at which phase, with which comparator — and which programs have gone quiet.
Read it
Interview
Our first one is still ahead of us
The reference publication in this field runs a strong interview line, and it is one of the reasons to read it. Ours starts empty, and saying so plainly beats filling the space with quotes lifted from other people’s conversations and presented as our own reporting.
What we would want from a first one is narrow and checkable: a principal investigator on the design decision they would change, a state regulator on what the licensing data actually shows, a facilitator on the screening question that turns people away. When one is published it appears here with the subject named and the date on it.
Be there for the first one
The monthly briefing carries every new piece of analysis, and it will carry the interviews as they land. One email a month, and the workbook arrives first.
The workbook arrives right away, then a monthly briefing. Unsubscribe in a click.
Common questions